Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic
•
0 likes•26 views
Chair and Presenters Taofeek K. Owonikoko, MD, PhD, Anne Chiang, MD, PhD, FASCO, and Jared Weiss, MD, prepared useful Practice Aids pertaining to small cell lung cancer for this CME/MOC/AAPA/IPCE activity titled “Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/426IDlG. CME/MOC/AAPA/IPCE credit will be available until March 23, 2025.
Recommended
Recommended
More Related Content
Similar to Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic
Similar to Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic (20)
More from PVI, PeerView Institute for Medical Education
More from PVI, PeerView Institute for Medical Education (20)
Recently uploaded
Recently uploaded (20)
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic
- 1. SCLC Treatment Algorithm1-3,a Full abbreviations, accreditation, and disclosure information available at PeerView.com/FUR40 a This algorithm was created by Aakash Desai, MBBS, MPH, and used with his permission. 1. Paz-Ares L et al. ESMO Open. 2022;7:100408. 2. Paz-Ares L et al. ESMO 2021. Abstract LBA61. 3. NCCN Clinical Practice Guidelines in Oncology. Small Cell Lung Cancer. Version 2.2024. https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. CT abdomen/pelvis, PET/CT scan (if needed), MRI brain, PFTs, bone marrow biopsy (select cases), mediastinal staging (stage I-IIA) Stage and Workup Is Cancer confined to one hemithorax and regional lymph nodes (can be treated with single radiation field)? !"#"$%&'($)*% ?#*@*&#($2,'$+'(%+3(-+$,2$0"'%+*)($*-+(-+ Limited-Stage Disease Eligible for treatment of curative intent %4$%5("6%'($)*% Extensive-Stage Disease Stage III/IV disease; not eligible for treatment of curative intent YES NO STAGE I-IIA STAGE IIB-IIIC Pathologic mediastinal staging Positive Negative Platinum-based chemotherapy + concurrent RT (PS 0-2) or ± RT (PS 3-4 due to SCLC) JCOG 9104: Concurrent RT vs sequential RT • mOS: 27.2 vs 19.7 mo • HR: 0.70 Lobectomy + mediastinal LN dissection or sampling Platinum-based chemotherapy Platinum-based chemotherapy + mediastinal RT R0, N0 R0, N+ and/or R1-2 Take into account PS, comorbidities, and age Meta-analysis: PCI vs no PCI RR of death HR: 0.84 (P = .01) Prophylactic Cranial Irradiation in Patients Achieving Remission (ALL Stages) PS ≤2 or ≥3 due to SCLC PS ≥3 not due to SCLC Individualized therapy in consult with palliative medicine 1L: Chemo-immunotherapy If ineligible for immunotherapy, use platinum- based chemotherapy >6 mo CTFI? Relapse Yes No 2L: Chemotherapy 2L: Chemotherapy Carboplatin + etoposide + atezolizumab with maintenance atezolizumab IMpower133: Chemo + atezo vs chemo • mOS: 12.3 vs 10.3 mo • HR: 0.76 Carboplatin or cisplatin + etoposide + durvalumab with maintenance durvalumab CASPIAN: Chemo + durva vs chemo • mOS: 12.9 vs 10.5 mo • HR: 0.71 Rechallenge with original platinum-based chemotherapy (preferred) Lurbinectedin (recommended) Phase 2 basket trial: Single arm • ORR: 35.2% • mDOR: 5.1 mo For complete treatment recommendations and regimens, refer to the NCCN guidelines Lurbinectedin (preferred) Phase 2 basket trial: Single arm • ORR: 35.2% • mDOR: 5.1 mo Topotecan (preferred) Trial: Topotecan vs CAV • ORR: 23.3% vs 18.3% Clinical trials (preferred) For complete treatment recommendations and regimens, refer to the NCCN guidelines Clinical trials (preferred) T1-2, N0, M0 T3-4, N0, M0 T1-4, N1-3, M0 ?
- 2. Research Trends and Emerging Therapies in SCLC Full abbreviations, accreditation, and disclosure information available at PeerView.com/FUR40 1. Gay MG et al. Cancer Cell. 2021;39:346-360. Clinical Studies Informing the Use of Current Therapy Transcriptional Signatures, Subtypes, and Therapeutic Vulnerabilities1 Novel Therapeutic Approaches on the Horizon Selected Studies for Immunotherapy in LS-SCLC Selected Studies for First- and Later-Line ES-SCLC Bispecific T-Cell Engager (BiTE) Antibody–Drug Conjugates (ADCs) ADRIATIC Phase 3 trial of durvalumab or durvalumab + tremelimumab as consolidation treatment in LS-SCLC NRG/Alliance LU005 Phase 2/3 trial of atezolizumab ± cCRT in LS-SCLC ASTRUM-005 Phase 3 trial of 1L serplulimab + chemo vs chemo in ES-SCLC KEYVIBE-008 Phase 3 trial of 1L vibostolimab + pembrolizumab + chemo vs atezolizumab + chemo in ES-SCLC NCT04702880 Phase 2 trial of 1L BMS-986012 + nivolumab + chemo in ES-SCLC LAGOON Confirmatory phase 3 trial of lurbinectedin in relapsed SCLC IMforte Phase 3 trial of lurbinectedin + atezolizumab as maintenance therapy in ES-SCLC following 1L immunochemotherapy LUPER Phase 1/2 trial of lurbinectedin + pembrolizumab in relapsed SCLC DeLLphi-300 Phase 1 trial of tarlatamab monotherapy or in combination with ICIs in SCLC ORR: 23%, mPFS: 3.7 mo; mOS: 13.2 mo DeLLphi-301 Phase 2 trial of tarlatamab in ≥3L SCLC ORR: 40% for 10-mg group, 32% for 100-mg group mPFS: 4.9 mo for 10-mg group, 3.9 mo for 100-mg group NCT04145622 Phase 1/2 FIH trial of ifinatamab deruxtecan (B7-H3 targeting ADCs) in solid tumor, including SCLC NCT05280470 Phase 2 trial of ifinatamab deruxtecan in pre-treated ES-SCLC IMMU-132-01 Phase 1/2 trial of sacituzumab govitecan (TROP2 targeting ADCs) in epithelial cancer, including SCLC Antibody Chemo drug + = Antibody–drug conjugates FDA priority review